Evidence map›Paper›PMID 36679900›Full record

ReviewVaccines2022

Macrophages as a Potential Immunotherapeutic Target in Solid Cancers.

Alok K Mishra, Shahid Banday, Ravi Bharadwaj, Amjad Ali, Romana Rashid, Ankur Kulshreshtha, Sunil K Malonia

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Significance of the Microenvironment in T/Nk-Cell Neoplasms.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Green Nanotechnology ofNanotechnology, science and applications · 2023
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alok K MishraDepartment of Molecular, Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-7742-2426
Shahid BandayDepartment of Molecular, Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0001-8539-6662
Ravi BharadwajDepartment of Medicine, UMass Chan Medical School, Worcester, MA 01605, USA.
Amjad AliDepartment of Molecular, Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.
Romana RashidDepartment of Medicine, UMass Chan Medical School, Worcester, MA 01605, USA.
Ankur KulshreshthaDepartment of Molecular, Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.
Sunil K MaloniaDepartment of Molecular, Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-2727-5165
University of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The revolution in cancer immunotherapy over the last few decades has resulted in a paradigm shift in the clinical care of cancer. Most of the cancer immunotherapeutic regimens approved so far have relied on modulating the adaptive immune system. In recent years, strategies and approaches targeting the components of innate immunity have become widely recognized for their efficacy in targeting solid cancers. Macrophages are effector cells of the innate immune system, which can play a crucial role in the generation of anti-tumor immunity through their ability to phagocytose cancer cells and present tumor antigens to the cells of adaptive immunity. However, the macrophages that are recruited to the tumor microenvironment predominantly play pro-tumorigenic roles. Several strategies targeting pro-tumorigenic functions and harnessing the anti-tumorigenic properties of macrophages have shown promising results in preclinical studies, and a few of them have also advanced to clinical trials. In this review, we present a comprehensive overview of the pathobiology of TAMs and their role in the progression of solid malignancies. We discuss various mechanisms through which TAMs promote tumor progression, such as inflammation, genomic instability, tumor growth, cancer stem cell formation, angiogenesis, EMT and metastasis, tissue remodeling, and immunosuppression, etc. In addition, we also discuss potential therapeutic strategies for targeting TAMs and explore how macrophages can be used as a tool for next-generation immunotherapy for the treatment of solid malignancies.

Indexed as

cancer stem cellsCAR macrophagesCD47clinical trialsCSF1Rdrug resistanceimmunotherapyinflammationmetastasisphagocytosisprognosisTAMs

Identifiers

PMID36679900
PMCPMC9863216
OpenAlexW4312202257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.